Awaited for 2 years, the vaccine developed by the French laboratory Sanofi once morest the coronavirus is finally on the market. Since December 22, it can be found in France in pharmacies. It is a recombinant protein vaccine and its use is particularly recommended for booster doses by the High Authority for Health. It concerns people aged 18 and over.
The Sanofi vaccine (VidPrevtyn Beta) at recombinant protein has received a favorable opinion of use of the Haute Autorité de santé on December 8 as well as Nuvaxovid from Novavax already used as a primary injection.
Since December 22, the Sanofi vaccine has been distributed in pharmacies in France and should be in Guyana by January.
Undoubtedly good news for all those who remain resistant to being vaccinated with the Pzifer messenger RNA vaccine mainly used in Guyana. But currently, according to the latest official sources from ARS Guyana, less than half of the population over the age of 12 has received a vaccine once morest covid.
This new vaccine is put on the market while we are witnessing a resurgence of the coronavirus epidemic throughout the country.
A campaign is being carried out so that those vaccinated who have received 2 or 3 doses, “a new dose is recommended 3 months following the last booster for people over 80 and the immunocompromised, and 6 months for everyone else: people over 60, those under 60 with comorbidities, pregnant women, as well as for those around them”.
If in Guyana the Covis-19 epidemic seems to be maintained in acceptable proportions, nevertheless, caution remains in order as well as a reminder of the usual precautions to be taken: wearing a mask in busy public places as well as regular hand cleaning.
